Evidence map›Paper›PMID 41213949›Full record

ArticleCell death & disease2025

Dual effects of the alternative spliced RIG-I isoform PTIR1 on host antiviral defense and immune homeostasis.

Jia Song, Wenyu Tian, Lulu Liu, Xuyang Zhao, Wei Zhao, Dan Lu

Abstract read
In one paragraph

Article in Cell death & disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Jia SongDepartment of Dental Materials & Dental Medical Devices Testing Center, Peking University School and Hospital of Stomatology, Beijing, PR China.
Wenyu TianInstitute of Systems Biomedicine, School of Basic Medical Sciences, NHC Key Laboratory of Medical Immunology, Beijing Key Laboratory of Tumor Systems Biology, Peking University, Beijing, PR China.
Lulu LiuDepartment of Geriatric Dentistry, Peking University School and Hospital of Stomatology, Beijing, PR China.
Xuyang ZhaoInstitute of Systems Biomedicine, School of Basic Medical Sciences, NHC Key Laboratory of Medical Immunology, Beijing Key Laboratory of Tumor Systems Biology, Peking University, Beijing, PR China.ORCID http://orcid.org/0000-0002-4470-7986
Wei ZhaoDepartment of Clinical Laboratory, China-Japan Friendship Hospital, Beijing, PR China. zhaowei@zryhyy.com.cn.ORCID http://orcid.org/0000-0003-2498-1272
Dan LuInstitute of Systems Biomedicine, School of Basic Medical Sciences, NHC Key Laboratory of Medical Immunology, Beijing Key Laboratory of Tumor Systems Biology, Peking University, Beijing, PR China. taotao@bjmu.edu.cn.ORCID http://orcid.org/0000-0002-3000-5094

Funding

China Postdoctoral Science Foundation 2022M720008National Natural Science Foundation of China (National Science Foundation of China) 82171826National Natural Science Foundation of China (National Science Foundation of China) 82301076
6 · The paper itself

Abstract

Efficient pathogen recognition must be tightly regulated to prevent immunopathology. Here, we identify PTIR1, a primate-specific splice variant of DDX58 lacking exon 4 and encoding a truncated RIG-I isoform, as a negative regulator of innate immune signaling. PTIR1 is selectively induced upon viral infection or interferon (IFN) stimulation, and its ectopic expression via adenoviral delivery broadly suppresses inflammatory responses in vivo. Mechanistically, PTIR1 activates the deubiquitinase UCHL5 to limit STAT1 ubiquitination at lysine 525, thereby impairing STAT1 nuclear translocation and dampening type I and type II IFN responses. Accordingly, in a model of autoimmune hepatitis, PTIR1 restricts IFN-γ-driven inflammation, and in a viral infection model, it attenuates type I IFN responses. PTIR1 also modulates RIG-I signaling by interfering with its dimerization, reducing its ubiquitination, and disrupting its interaction with MAVS, thereby limiting RIG-I-mediated antiviral recognition and facilitating viral immune evasion. These findings identify PTIR1 as an inducible post-transcriptional checkpoint that fine-tunes antiviral and inflammatory signaling to preserve tissue integrity.

Indexed as

Alternative SplicingDEAD Box Protein 58HomeostasisAnimalsHEK293 CellsHumansImmunity, InnateMiceMice, Inbred C57BLProtein IsoformsReceptors, ImmunologicSignal TransductionSTAT1 Transcription FactorUbiquitinationUbiquitin ThiolesteraseDEAD Box Protein 58Protein IsoformsReceptors, ImmunologicRIGI protein, humanSTAT1 Transcription FactorUbiquitin Thiolesterase

Identifiers

PMID41213949
PMCPMC12603114

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.